Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3584 - Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group


10 Oct 2016


Poster display


Michail Nikolaou


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


M. Nikolaou, E. Saloustros, A. Polyzos, C. Christophyllakis, N. Kentepozidis, L. Vamvakas, K. Kalbakis, S. Agelaki, V. Georgoulias, D. Mavroudis

Author affiliations

  • Medical Oncology, Hellenic Oncology Research Group (HORG), 11471 - Athens/GR


Abstract 3584


Triple negative breast cancer (TNBC) is a heterogeneous classification to which various subtypes are included. At present, TNBC lacks a standard targeted therapeutic strategy, other than conventional cytotoxic agents. The combination of weekly carboplatin and paclitaxel is active and well tolerated. In addition, bevacizumab when added to paclitaxel prolonged progression-free survival (PFS) in metastatic breast cancer (MBC). We investigated the activity and toxicity of paclitaxel plus carboplatin and bevacizumab as first-line treatment in triple-negative MBC.


The primary endpoint was the objective response rate (ORR) [complete (CR) + partial remission (PR)] and safety of the combination. The study followed the Simon's two-stage optimal design with 16 patients initially evaluated for response and toxicity and then expanding to a total of 46 patients. The null hypothesis that the objective response rate is ≤40% could be rejected if the number of CR/PR was ≥23. Paclitaxel 90mg/m2 and carboplatin AUC 2 were administered on days 1, 8, and 15 every 4 weeks, preceded by bevacizumab 10 mg/kg on days 1 and 15.


Forty-five women with triple negative MBC have been recruited thus far. Of them, 13 were premenopausal and 27 had prior (neo-) adjuvant chemotherapy. The median cycles administered were 6 (range: 1-8). We observed 7 CR, 23 PR for an ORR of 66.7%. Seven patients achieved stable disease, while 8 had disease progression. Median duration of response was 18.2 months and median PFS 10.3 months. Median overall survival was 25.7 months and 1-year survival 75.6%. Neutropenia grade 3 and 4 was experienced by 13 (29,5%) and 6 (13,6%) patients respectively, with one toxic death due to febrile neutropenia. Other grade 3 toxicities included anemia/neurotoxicity (4,4%), thrombocytopenia/diarrhea (2,2%).


Our study has achieved the primary objective of demonstrating clinical activity for weekly carboplatin and paclitaxel in combination with bevacizumab in triple negative MBC. We believe the combination merits further evaluation in this population.

Clinical trial identification


Legal entity responsible for the study



Hellenic Oncology Research Group (HORG)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings